The takeaway
Olema Pharmaceuticals Inc shows a pronounced seasonal pattern over 6 years of data — strongest in June (+18.6%) and softest in February (−19.8%).
Right now
In July, the stock has risen 60% of years, averaging +13.6%, about +11.4 pts better than the S&P 500.
The full picture
Olema Pharmaceuticals Inc's most dependable month has been June, higher in 3 of 5 years; February has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | — | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in November (+19.4 pts); it has trailed the market most in February (−19.5 pts).
“vs S&P” is Olema Pharmaceuticals Inc’s average for a month minus the S&P 500’s average for that same month — isolating Olema Pharmaceuticals Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, June has closed higher 60% of the time versus 60% across the last 6 years — the pattern is holding.
Figures are the typical (median) June return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
June looks the standout, up in 3 of 5 Junes — yet the appeal is lumpy, leaning on the occasional blow-out year rather than dependable strength.
The headline flatters a touch — its +18.6% average sits well above the +1.2% a typical year delivers, the work of a few big Junes. That reliability comes with real swings, mind — even June ranges by 27.0% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: June has cleared the S&P 500 by +18.4 points above the index.
The strength clusters rather than stands alone — June–September forms a firm stretch that carries much of the year. On the other side of the ledger, February has been the soft spot — the weakest of 4 months that average a loss (−19.8%), and the edge isn't year-round — the stock has trailed the S&P 500 in February, March, and December. Its roughest month on record was a −67.6% November in 2021 — a reminder of how hard even a seasonal name can fall.
Hold it loosely, then: the June tendency is genuine but lumpy, more about the occasional outsized year than a gain to bank on. With a short 6-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (June), its worst (February), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2020 its best month (June, +18.6%) has run well ahead of its worst (February, −19.8%) — the heatmap above shows how steady that gap has been year to year.
June has been the strongest, averaging +18.6% and closing higher in 3 of 5 years since 2020.
It's the weakest, averaging −19.8% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade